Twitter, the JOBS Act, and Return to IPO Normalcy

Twitter, the JOBS Act, and Return to IPO Normalcy
November 8, 2013

John Berlau

John Berlau is a senior fellow for finance and access to capital at the Competitive Enterprise... (read full bio)

The headline read that the company's initial public offering price is "high," and "so is its valuation." The accompanying story explained that the latest tech sensation had yet to show a profit, and had in fact been losing millions per year.

An analyst attributed what the article called the stock's "high valuation" to "Internet inhalant." He said, "Some people smoke Internet inhalant and their judgment gets bizarre."

Think this is an article about the Twitter initial public offering IPO that debuted yesterday? Wrong! It's a piece from Wired in 1997 on the new IPO of Amazon.com.

Like Twitter, Amazon was losing money when it went public. In fact, investors would have to wait more than four years after its IPO for the firm to turn its first profit.

Yet investors who bought Amazon at its IPO price sure have turned a profit. According to GeekWire, $1000 invested in Amazon back then would have turned into $239,045 today!

My organization, The Competitive Enterprise Institute, is not in the business of  making stock market predictions. Twitter's IPO may soar or it may pop, and whichever result should make no difference for public policy.

Shutting Out Individual Investors

What should concern policymakers, however, is whether middle-class retail investors, informed of the risks, have the opportunities to build wealth through investing in firms at their growth stages. The soaring regulatory costs of "reforms" such as the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Act of 2010 caused companies to delay going public as long as possible, denying ordinary investors such opportunities.

New companies formed in the post-Sarbox era, such as Facebook, would seek funding from "accredited" investors such as hedge funds and venture capital firms to avoid the red tape. When they went public, as Facebook did last year in its disastrous IPO, much of the growth had already occurred. The main objective of such IPOs was not capital for growth, but for existing owners to realize value of their shares.

Facebook's stock is doing well now and above its IPO price. But the real "scandal," if any, is that ordinary shareholders couldn't get a piece of it while it was growing due to the red tape.

Regulatory Relief Spurring Earlier IPOs

The good news is that the Jumpstart Our Business Startups (JOBS) Act, signed by President Obama last year, has started a partial reversal of this trend. Because small and midsize companies can now get relief from some of the most onerous provisions of Sarbox and Dodd-Frank for five years after the launching their IPOs, hundreds more firms have gone public during their growth stages.

As I have written previously, and others have noted, Twitter likely went public earlier than expected due to the JOBS Act's regulatory relief provisions. In the “Form S-1” Twitter filed to launch its IPO, the company declares, “We are an emerging growth company, and . . .  we may choose to take advantage of exemptions from various reporting requirements under the JOBS Act.”

Yet companies that go public before making their first profit are not products of the so-called radicalism of the JOBS Act, nor were they aberrations of the go-go '90s era in which Amazon listed.

Going public before profitability was in fact the historical norm before Sarbox. Xerox, which went public in the 1930s, struggled with meager revenues for decades until its revolutionary photocopier debuted in 1959, causing sales, profits, and its stock price to skyrocket over the next decade.

Need for More Relief

Ironically, Twitter's eligibility for JOBS Act relief may end as early if its stock price rises high enough to put it outside of the law's threshold of $700 million in market valuation. The only JOBS Act provisions the company then would have benefited from would be the pre-IPO reg relief.

Such things could also happen to firms such as biotechnology companies, many of which have utilized JOBS Act reg relief, when there is sudden interest in a new drug they are developing. The company may still be small, but investor demand will cause its market cap to be too large. The firms would then have to spend much more time dealing with the minutiae of Sarbox "internal controls" rather than growth for investors by developing new products.

Such issues should be addressed in a "JOBS Act 2.0," outlines of which are reportedly under discussion. In the meantime, we should celebrate the JOBS Act's bipartisan success in increasing opportunities for smaller entrepreneurs and investors to snap up growth and build wealth.

Disclosure: John Berlau owns shares in Facebook but is still not on Facebook.

Used with permission of the Competitive Enterprise Institute’s Openmarket.org blog.

 

 

 

 

John Berlau

John Berlau is a senior fellow for finance and access to capital at the Competitive Enterprise... (read full bio)